期刊文献+

人凝血因子Ⅷ制品配方研究 被引量:1

Formulation research of human coagulation factorⅧ product
下载PDF
导出
摘要 目的摸索一种适用于人凝血因子Ⅷ制品的配方。方法以人凝血因子Ⅷ质量为指标,进行成分筛选实验,对选定的成分再进行剂量选择,获得最终配方、制备成品。进行质量与安全性、稳定性考察,评估最终配方的效果。结果得到的配方效果令人满意,经稳定性(2-8℃、24个月;25℃、24个月;40℃、6个月)考察证明配方稳定有效。结论研发出一种适合人凝血因子Ⅷ制品的配方。 Objective To search for a formulation suitable for human coagulation factor Ⅷ (FⅧ) product .Methods By using the human FⅧ quality as the indicator ,the compositions screening experiment was conducted ,then the dosage selection was per‐formed on the selected compositions ,finally the formulation was obtained for prepaing the FⅧ product .The quality ,safety and sta‐bility were investigated .The effect of final formulation was evaluated .Results The effect of obtained formulation was satisfactory , which was proved to be stable and effective by the stability test (2-8 ℃ × 24 months ,25 ℃ × 24 months ,40 ℃ × 6 months) .Con‐clusion The formulation of FⅧ product suitable for human is developed .
出处 《国际检验医学杂志》 CAS 2015年第8期1015-1017,共3页 International Journal of Laboratory Medicine
基金 国家高技术研究发展计划(863计划)项目(2012AA021904)
关键词 人凝血因子Ⅷ 配方研究 效价回收率 human coagulation factor Ⅷ formulation research titer recovery
  • 相关文献

参考文献11

  • 1Winkelman L, Feldman PA, Evans DR. Severe heat treatment of lyophilied coagulation factors [J ]. Curr Stud Hematol Blood Transfus, 1989,56 (1) : 55-69.
  • 2Skidmore SJ,Pasi KJ, Mawson SJ, et al. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A,non-B hepatitis[J]. J Med Virol,1990,30(1) :50-52.
  • 3Hart HF, Hart WG, Crossley J, et al. Effect of terminal(dry) heat treatment on non-enveloped viruses in coagulation factor concen- trates[J]. Vox Sang, 1994,67(4) :345-350.
  • 4Mark Brooker. Registry of Clotting Factor Concentrates[M]. 8th edn. In Facts and Figures, no. 6. Montreal: World Federation of Hemophilia, 2008 : 10-14.
  • 5Carpenter JF,Pikal MJ,Chang BS, et al. Rational design of stable lyophilized protein formulations:some practical advice[J]. Pharm Res, 1997,14(8) : 969-975.
  • 6Osterberg T, Fatouros A, Mikaelsson M. Development of freeze- dried albumin-free formulation of recombinant factor vIn SQ[J]. Pharm Res, 1997,14 (7) : 892-898.
  • 7CSL Behring. Biostate instruction [ EB/OL]. (2013-11-30) [2014-08-11] http://labeling, cslbehring, eom/PI/AU/Biostate/ EN/Biostate-Prescribing-Information. pdf.
  • 8Cutter Biological. Koate DVI instruetion[EB/OL]. (2012-08-31) [2014-08-30]http://www. koate-dvi, corn/documents/809754/0/ Koate_DVI. pdf/fb455459-Sae0-43d3-bb48-363389a7cSc3.
  • 9Grifols. Alphanate instruetion[EB/OL]. (2008-12-28) [2014-10- 09] http://www, grifols, com/documents/10192/65508/ft_ al- phanate_eeuu, en/agf2fgcg-O5eb-4fac'-a7d3-5fOglc198cff version= 1.4.
  • 10CSL Behring. HUMATE-P instruction[EB/OL]. (2013-08-23) [2014-10-21] http//lahelng, eslhehring, eom/Pl/US/Humate- P/EN/Humate-P-Prescribing-Information. pdf.

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部